Elongation factor 2 in cancer: a promising therapeutic target in protein translation.

Cell Mol Biol Lett

Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450000, Henan, China.

Published: December 2024

Aberrant elongation of proteins can lead to the activation of oncogenic signaling pathways, resulting in the dysregulation of oncogenic signaling pathways. Eukaryotic elongation factor 2 (eEF2) is an essential regulator of protein synthesis that precisely elongates nascent peptides in the protein elongation process. Although studies have linked aberrant eEF2 expression to various cancers, research has primarily focused on its structure, highlighting a need for deeper exploration into its molecular functions. In this review, recent advancements in the structure, guanosine triphosphatase (GTPase) activity, posttranslational modifications, regulatory factors, and inhibitors of eEF2 are summarized. These findings provide a comprehensive cognition on the critical role of eEF2 and its potential as a therapeutic target in cancer. Furthermore, this review highlights important unanswered questions that warrant investigation in future research.

Download full-text PDF

Source
http://dx.doi.org/10.1186/s11658-024-00674-7DOI Listing

Publication Analysis

Top Keywords

elongation factor
8
therapeutic target
8
oncogenic signaling
8
signaling pathways
8
elongation
4
factor cancer
4
cancer promising
4
promising therapeutic
4
target protein
4
protein translation
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!